PCA3 and Familial prostate cancer: Importantly, the LBXexo score had a higher specificity than PCA3 in predicting biopsy results, with 60.5% vs. 34.9% and 57.1% vs. 36.7% for any-grade and high-grade prostate cancer, respectively (Table 3).